Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma
In light of a global rise in the number of patients with type 2 diabetes mellitus (T2DM) and obesity, non-alcoholic fatty liver disease (NAFLD), now known as metabolic dysfunction-associated fatty liver disease (MAFLD) or metabolic dysfunction-associated steatotic liver disease (MASLD), has become t...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-01-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1336216/full |
| _version_ | 1827378786339913728 |
|---|---|
| author | Yumin Wang Joshua S. Fleishman Tongda Li Yulin Li Zhao Ren Jichao Chen Mingchao Ding |
| author_facet | Yumin Wang Joshua S. Fleishman Tongda Li Yulin Li Zhao Ren Jichao Chen Mingchao Ding |
| author_sort | Yumin Wang |
| collection | DOAJ |
| description | In light of a global rise in the number of patients with type 2 diabetes mellitus (T2DM) and obesity, non-alcoholic fatty liver disease (NAFLD), now known as metabolic dysfunction-associated fatty liver disease (MAFLD) or metabolic dysfunction-associated steatotic liver disease (MASLD), has become the leading cause of hepatocellular carcinoma (HCC), with the annual occurrence of MASLD-driven HCC expected to increase by 45%–130% by 2030. Although MASLD has become a serious major public health threat globally, the exact molecular mechanisms mediating MASLD-driven HCC remain an open problem, necessitating future investigation. Meanwhile, emerging studies are focusing on the utility of bioactive compounds to halt the progression of MASLD to MASLD-driven HCC. In this review, we first briefly review the recent progress of the possible mechanisms of pathogenesis and progression for MASLD-driven HCC. We then discuss the application of bioactive compounds to mitigate MASLD-driven HCC through different modulatory mechanisms encompassing anti-inflammatory, lipid metabolic, and gut microbial pathways, providing valuable information for future treatment and prevention of MASLD-driven HCC. Nonetheless, clinical research exploring the effectiveness of herbal medicines in the treatment of MASLD-driven HCC is still warranted. |
| first_indexed | 2024-03-08T13:01:54Z |
| format | Article |
| id | doaj.art-0ef59ef5fb424999843a99ff9d77c801 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-03-08T13:01:54Z |
| publishDate | 2024-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-0ef59ef5fb424999843a99ff9d77c8012024-01-19T04:50:20ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122024-01-011410.3389/fphar.2023.13362161336216Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinomaYumin Wang0Joshua S. Fleishman1Tongda Li2Yulin Li3Zhao Ren4Jichao Chen5Mingchao Ding6Department of Respiratory and Critical Care Medicine, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, ChinaDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John’s University, Queens, NY, United StatesDepartment of Traditional Chinese Medicine, Beijing Geriatric Hospital, Beijing, ChinaDepartment of Respiratory and Critical Care Medicine, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, ChinaDepartment of Pharmacy, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, ChinaDepartment of Respiratory and Critical Care Medicine, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, ChinaDepartment of Peripheral Vascular Intervention, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, ChinaIn light of a global rise in the number of patients with type 2 diabetes mellitus (T2DM) and obesity, non-alcoholic fatty liver disease (NAFLD), now known as metabolic dysfunction-associated fatty liver disease (MAFLD) or metabolic dysfunction-associated steatotic liver disease (MASLD), has become the leading cause of hepatocellular carcinoma (HCC), with the annual occurrence of MASLD-driven HCC expected to increase by 45%–130% by 2030. Although MASLD has become a serious major public health threat globally, the exact molecular mechanisms mediating MASLD-driven HCC remain an open problem, necessitating future investigation. Meanwhile, emerging studies are focusing on the utility of bioactive compounds to halt the progression of MASLD to MASLD-driven HCC. In this review, we first briefly review the recent progress of the possible mechanisms of pathogenesis and progression for MASLD-driven HCC. We then discuss the application of bioactive compounds to mitigate MASLD-driven HCC through different modulatory mechanisms encompassing anti-inflammatory, lipid metabolic, and gut microbial pathways, providing valuable information for future treatment and prevention of MASLD-driven HCC. Nonetheless, clinical research exploring the effectiveness of herbal medicines in the treatment of MASLD-driven HCC is still warranted.https://www.frontiersin.org/articles/10.3389/fphar.2023.1336216/fullhepatocellular carcinomanon-alcoholic fatty liver diseasemetabolic dysfunction-associated steatotic liver diseasenatural productstreatment |
| spellingShingle | Yumin Wang Joshua S. Fleishman Tongda Li Yulin Li Zhao Ren Jichao Chen Mingchao Ding Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma Frontiers in Pharmacology hepatocellular carcinoma non-alcoholic fatty liver disease metabolic dysfunction-associated steatotic liver disease natural products treatment |
| title | Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma |
| title_full | Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma |
| title_fullStr | Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma |
| title_full_unstemmed | Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma |
| title_short | Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma |
| title_sort | pharmacological therapy of metabolic dysfunction associated steatotic liver disease driven hepatocellular carcinoma |
| topic | hepatocellular carcinoma non-alcoholic fatty liver disease metabolic dysfunction-associated steatotic liver disease natural products treatment |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2023.1336216/full |
| work_keys_str_mv | AT yuminwang pharmacologicaltherapyofmetabolicdysfunctionassociatedsteatoticliverdiseasedrivenhepatocellularcarcinoma AT joshuasfleishman pharmacologicaltherapyofmetabolicdysfunctionassociatedsteatoticliverdiseasedrivenhepatocellularcarcinoma AT tongdali pharmacologicaltherapyofmetabolicdysfunctionassociatedsteatoticliverdiseasedrivenhepatocellularcarcinoma AT yulinli pharmacologicaltherapyofmetabolicdysfunctionassociatedsteatoticliverdiseasedrivenhepatocellularcarcinoma AT zhaoren pharmacologicaltherapyofmetabolicdysfunctionassociatedsteatoticliverdiseasedrivenhepatocellularcarcinoma AT jichaochen pharmacologicaltherapyofmetabolicdysfunctionassociatedsteatoticliverdiseasedrivenhepatocellularcarcinoma AT mingchaoding pharmacologicaltherapyofmetabolicdysfunctionassociatedsteatoticliverdiseasedrivenhepatocellularcarcinoma |